Lantheus Holdings, Inc.

LNTH Healthcare Drug Manufacturers Specialty & Generic

Lantheus Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, up 0.50% from fiscal 2024.

Revenue
+1.54%
EPS
−16.4%
Free cash flow
+7.71%
Total debt
+0.52%

Quarter to September 2026, against a year earlier

100.65 0.05 −0.05%
Market cap
$6.6B
P/E
24.3×
Fwd P/E
21.3×
Dividend yield
—
F-score
5/9
Altman Z
4.25
Beneish M
−2.23
Dividend safety
n/a
Sep '26 Jun '26 Mar '26 Dec '25 Older periods
Piotroski F-Score
7 5 5 5

+8 more TTM periods

ROE
21.81% 22.21% 23.48% 21.45%
ROA
11.41% 12.15% 12.68% 11.10%
ROIC
14.62% 14.65% 14.12% 14.94%
Return on Tangible Assets
29.10% 32.59% 36.39% 31.98%
Average Days of Receivables
80.77 83.04 84.31 88.56
Free Cash Flow per Share
6.02 6.03 5.90 5.25
Free Cash Flow
393.09 392.83 382.11 354.05
Other line items

Show all line items

Columns are period end dates · fundamentals updated 6 Nov 2026